Electra Therapeutics arrived on the public markets last week with an unusually active register: a 13D activist filing from its largest shareholder, $20 million in disclosed open-market buying at the IPO price, and a stock already trading 17% below where insiders put their money just nine days ago.
The ownership story is the most consequential fact about ETRA right now. OrbiMed Advisors filed a Schedule 13D on September 25, disclosing an 11% stake of 6.9 million shares. A 13D signals activist or engagement intent, distinct from the passive 13G that most institutional holders file at the 5% threshold. That makes OrbiMed's position one of the more newsworthy ownership facts a newly public biotech can carry. Two other holders, Redmile Group at 8.7% and LSP 7 Cooperatief at 6.0%, filed 13G disclosures on September 28. The four largest institutional positions collectively account for more than 34% of the company, a concentrated register typical of a freshly listed clinical-stage name. As with all 13D/G filings, these stakes are as last disclosed around the 5% threshold; holders dropping below that level are not required to update their filings.
The insider buying that accompanied the listing is the sharpest signal in the data. Carl Gordon, a director and 10% owner, put $20 million to work in open-market purchases on September 21, buying 1.333 million shares across two transactions at $15.00 each. Neither transaction was conducted under a 10b5-1 pre-arranged trading plan, making both discretionary commitments. OrbiMed also appears in the filing as a co-purchaser, adding a further 333,333 shares at $15.00 for roughly $5 million. The 90-day net insider figure across all Form 4 activity comes to 2.67 million shares with $40 million in disclosed value. For a company with no market cap currently reported and a float dominated by a handful of specialist biotech investors, that level of commitment from the register at the offering price is notable context.
The borrow market is loose, which cuts against any near-term squeeze narrative. Availability is extremely high at around 1,233%, meaning there are roughly 12 shares available to lend for every one already borrowed. Cost to borrow has been running in the low-to-mid 20% range this week, elevated for most names but unremarkable for a small, newly listed biotech. The ORTEX short score is a modest 37, toward the lower half of the range, consistent with limited short-side pressure at this stage. The stock is down 17% on the week, closing at $11.35 on September 29, which puts it roughly 24% below the $15 price at which insiders bought.
The clearest thing to watch from here is whether the gap between the $15 insider purchase price and the current $11.35 close narrows or widens into the company's first major clinical or financial disclosure. No earnings date is on record yet. With OrbiMed holding both an activist 13D stake and a board seat, and with Redmile and LSP among the other large holders, any company update will land against a register that is already on record with a strong view on where fair value sits.
See the live data behind this article on ORTEX.
Open ETRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
